Literature DB >> 14510951

Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity.

Rizwana Chohan1, Ravi Vij, Douglas Adkins, William Blum, Randy Brown, Michael Tomasson, Steven Devine, Timothy Graubert, Lawrence T Goodnough, John F DiPersio, Hanna Khoury.   

Abstract

Calcineurin inhibitor-induced central nervous system toxicities are uncommon and often resolve after discontinuation of the offending drug. The long-term outcome of these patients is, however, unknown. Resolution of symptoms occurred in 70% of 30 allografted recipients who developed calcineurin inhibitor-induced neurotoxicity. When patients were rechallenged with the same or a different calcineurin inhibitor, symptoms recurred in 41%, leading to permanent discontinuation of the drug. De novo or progressive acute graft-versus-host disease (GVHD) was observed in 54% of patients at a median of 7 d (range 1-70 d) after initial onset of neurotoxicity. The prognosis was grim, with 24 (80%) of these patients dying a median 33 d after the onset of neurotoxicity (range 2-594 d). GVHD and/or infection occurred in 54% and were the most common primary causes of death. We conclude that calcineurin inhibitor-induced neurotoxicity is frequently reversible but associated with a poor prognosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14510951     DOI: 10.1046/j.1365-2141.2003.04550.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

1.  Calcineurin inhibitor-induced irreversible neuropathic pain after allogeneic hematopoietic stem cell transplantation.

Authors:  Nobuharu Fujii; Kazuma Ikeda; Motoko Koyama; Kazutoshi Aoyama; Taro Masunari; Eisei Kondo; Takashi Matsuzaki; Satoshi Mizobuchi; Akio Hiraki; Takanori Teshima; Katsuji Shinagawa; Fumihiko Ishimaru; Mitsune Tanimoto
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 2.  Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features.

Authors:  W S Bartynski
Journal:  AJNR Am J Neuroradiol       Date:  2008-03-20       Impact factor: 3.825

3.  Thrombotic microangiopathy associated with sirolimus level after allogeneic hematopoietic cell transplantation with tacrolimus/sirolimus-based graft-versus-host disease prophylaxis.

Authors:  Sepideh Shayani; Joycelynne Palmer; Tracey Stiller; Xueli Liu; Sandra H Thomas; Tam Khuu; Pablo M Parker; Samer K Khaled; Stephen J Forman; Ryotaro Nakamura
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-15       Impact factor: 5.742

4.  Early central nervous system complications after allogeneic hematopoietic stem cell transplantation in children.

Authors:  Kyung Nam Koh; Meerim Park; Bo Eun Kim; Ho Joon Im; Jong Jin Seo
Journal:  Korean J Hematol       Date:  2010-09-30

5.  Long-term outcome following cyclosporine-related neurotoxicity in paediatric allogeneic haematopoietic stem cell transplantation.

Authors:  K Straathof; P Anoop; Z Allwood; J Silva; O Nikolajeva; R Chiesa; P Veys; P J Amrolia; K Rao
Journal:  Bone Marrow Transplant       Date:  2016-09-19       Impact factor: 5.483

6.  Cyclosporine A-related neurotoxicity after haploidentical hematopoietic stem cell transplantation in children with hematopathy.

Authors:  Yong Wang; Yongzhi Zheng; Jingjing Wen; Jinhua Ren; Xiaohong Yuan; Ting Yang; Jianda Hu
Journal:  Ital J Pediatr       Date:  2021-04-01       Impact factor: 2.638

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.